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A Ab bs st tr ra ac ct t
A large amount of experimental data collected over the last decade has shown that genomic
organization is very complex and has highlighted the fact that the current set of gene annotations
does not fully capture this complexity. Much of the RNA detected in a cell is found to originate
from outside the exons of annotated genes. Exons of annotated and unannotated transcripts
separated by large genomic distances can be joined together in chimeric transcripts. Any given
base-pair in a genome could be traversed by many protein-coding and non-coding RNAs. We
discuss the implications of these effects for our understanding of disease.
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The interpretation of sequence polymorphism data, such as
the data produced in large amounts from genome-wide
association studies, is largely based on the concept of a gene
as a stand-alone, separate genomic entity with discrete start
and end, as defined by the current genomic annotations. The
immediate logical corollary of this notion is that the effect of
a nucleotide change is most likely to be local, or at least
within the locus in which the change was found. However,
surveys aimed at an unbiased cataloguing of the transcripts
produced by human and other genomes, such as [1-7],
challenge the notion of a gene as a separate, discrete genomic
unit. This, in turn, may affect the interpretation of any nucleo-
tide change that is found to be associated with a certain
phenotype or a disease. Following the results of such surveys
of transcriptional output of human and other genomes [1-7],
the concept of a gene has expanded in several directions.
First, a multitude of different transcripts are made at any
given locus. Analysis of the existing expressed sequence tag
(EST) data suggests that a protein-coding locus can produce
at least 5.7 different transcripts [1,8]. Although only some of
these alternative transcripts seem to have protein-coding
capacity, this expands the number of transcripts that a given
exon can participate in. Logically, a nucleotide change in a
shared exon could affect any of the transcripts that share it,
and thus the phenotypic effect of a nucleotide change is
likely to be represented as a sum of the effects on the
transcripts that express it. It is likely that the profile of
expressed transcripts is different in each tissue [9], and the
effect of a nucleotide change could thus differ depending on
the repertoire of transcripts expressed by the locus in each
cell. In a simple example, as shown for the annotated trans-
cripts in Figure 1, the phenotype may show itself in a tissue
that expresses an exon overlapping the variant and not in
another tissue that expresses transcripts that skip that exon.
In a more complex case depicted in Figure 1, a polymorphic
nucleotide or stretch of nucleotides could be part of a coding
exon in one tissue and a non-coding exon in another; or it
could represent both a regulatory region of one group of
transcripts and an exon of another group of transcripts.
Even more complex scenarios are possible considering that a
large number of different isoforms could be expressed in any
given cell type.
Second, the annotation of genomic regions that are con-
sidered exonic is incomplete. Unbiased studies using rapid
amplification of cDNA ends (RACE) on the genes within the
1% of the genome chosen for the ENCODE project have
shown that almost half the exons detected in these experi-
ments do not overlap annotated exons [1]. Thus, a nucleotidechange in a ‘non-coding’ region may in fact underlie an as-
yet undiscovered exon. Overall, 90% of all genes have been
shown to have either a novel internal exon or a novel 5’ exon
in at least one of the 12 tissues tested [3].
In addition, the boundary of a gene may extend well beyond
the current annotation. A gene can have many boundaries
and, in fact, exons of different genes can participate in
creating chimeric transcripts. The above-mentioned RACE
experiments have shown that 68.4% of all genes had a 5’
extension in at least one tissue tested [3]. Novel 5’ exons
were found to be represented both by novel, unannotated
regions and by exons of other genes. Indeed, transcripts
connecting exons of nearby loci and more distant loci
separated by other genes on both strands were commonly
found [1-3]. In fact, 57% of loci that were extended at the 5’
end had a connection to an exon of an upstream gene [3]. A
majority of 5’ extensions (87%) reached over an annotated
gene [3]. Often 5’ extensions were tissue- or cell-line-
specific, suggesting that in different tissues the profile of
gene-gene connections could be different. Connections in
the ENCODE regions could be identified only up to genomic
distances of around 0.5 megabases (Mb). A continuation of
these studies on human chromosomes 21 and 22 found a
wealth of distant connections that span megabases of
genomic space [2].
These observations raise several questions. What are the
mechanisms responsible for the production of chimeric RNAs
encoded by genes separated by very long genomic stretches?
What are the functions, if any, of such chimeric RNAs and
what are the implications of the uncovered connections (gene
to gene or a novel distant exon to known gene) for cell biology
and disease? So far, the answers to these questions remain
unknown. However, copy number variants can affect the
expression of distant genes located megabases away from the
bounds of the variable region [10,11]. This shows that the
effect of a genomic change does not have to be limited to the
immediate vicinity of the change and could in fact result in
both local and distant effects.
A third direction in which the concept of a gene has
expanded results from the observation that transcripts
emanating from any given locus could be carriers of trans-
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Examples of the potential effects of different sequence polymorphisms on two hypothetical loci, A and B. In this scenario, locus A has two annotated
transcripts (RNA-1 and RNA-2, dark blue), expressed in different tissues. Sequence polymorphism 1 would affect an annotated exon of locus A that
occurs in the annotated transcript RNA-1 and in unannotated transcripts (RNA-4 and RNA-5, cyan) and not in RNA-2. Variant 2 would affect a coding
exon that is present in both the annotated coding transcripts and also in the non-coding transcript RNA-7. These are examples of polymorphisms that
would currently be considered to be the only likely ‘functional’ polymorphisms in locus A, as they are the only ones to affect the annotated transcripts,
RNA-1 and RNA-2. Polymorphisms 3-6 are ‘non-coding’ polymorphisms, with polymorphism 6 being relatively distant from locus A. However, in this
example, these polymorphisms in fact overlap unannotated transcripts (cyan) within locus A, some of which extend outside locus A or encode regulatory
small RNA molecules that act in trans on other loci. Polymorphism 3 overlaps a novel exon that is a part of unannotated transcripts RNA-4, RNA-5 and
RNA-6. It could thus affect transcripts derived from both locus A and locus B, whether the two loci are nearby or distant in the genome. Polymorphism
4 overlaps a regulatory region for unannotated transcripts RNA-5 and RNA-6 and the 5’ untranslated region of RNA-4. It could thus also affect
expression of transcripts from both locus A and locus B. Polymorphism 5 overlaps a regulatory region for a non-coding RNA (transcript RNA-7) that is a
precursor for a small RNA, a miRNA (RNA-8). Thus, this polymorphism and polymorphism 2, which also overlaps this non-coding RNA, could affect
expression of other loci regulated by this small RNA in trans. Polymorphism 6 affects a more distant region in the genome that is connected to locus A
by transcript RNA-9. All transcripts are shown transcribed from left to right; non-coding portions of transcripts are represented as thin boxes; coding
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Processing into a functional
small RNAacting non-coding RNAs, such as microRNAs (miRNAs) or
small nucleolar RNAs (snoRNAs) [5,12-14]. Thus, a poly-
morphism affecting either the sequence or the processing of
such an RNA molecule [15] could in fact affect the
expression of loci regulated by the small RNA in trans, with
potentially no effect on the locus in which the polymorphism
was found, as shown in a hypothetical scenario in Figure 1.
Such effects could be prevalent given that we now know the
repertoire of the small, non-coding transcripts in a human
cell to be far greater than the annotated classes of known
small RNAs, and that such novel small RNAs could be
carried by long RNA precursors [16,17].
Overall, these observations suggest that the identification of
a sequence variant should not be the logical end point that
automatically connects the locus that harbors it with a
phenotype, but rather a beginning of a set of experimental
procedures to unravel the effects of the variant. A necessary
prerequisite for such experiments is unraveling the com-
plexity of transcripts that either include the variant or
originate nearby, because the variant also could affect a
regulatory region of a novel transcriptional unit. Considering
the vast number of unannotated transcripts present in a cell,
it is important to directly characterize transcript complexity,
for example using RACE with oligonucleotides positioned in
or around the polymorphism in the biological samples of
interest, rather than relying solely on the existing genomic
annotations. One can envisage such analysis to be followed
by expression profiles to estimate the effects of a sequence
variant  on all transcripts that it can be associated with,
including the ones that could connect it to distant regions in
the genome. Such experiments could be followed by direct
perturbation of the candidate transcripts by knockdown or
overexpression to estimate their contribution to a phenotype.
In addition to aiding our interpretation of sequence
polymorphism data, the wealth of novel transcripts found in
the human genome, including the chimeric RNAs that
connect together distant regions in the genome, is mostly a
virgin territory for biomarker discovery. Unannotated
transcripts tend to be cell-type-specific [3,18] and thus
should be attractive diagnostic molecules. The potential of
non-coding RNAs as biomarkers has been shown by Reis et
al. [19,20]; however, this field remains mostly unexplored
because of the emphasis on annotated protein-coding
transcripts. Furthermore, novel protein-coding transcript
isoforms, specifically those of transcripts encoding proteins
amenable to small molecule modulation, could be additional
targets for small molecule therapeutics. In this respect, the
high cell-type specificity of novel transcripts should provide
an advantage: inhibition of a protein encoded by these
transcripts is likely to be specific to a tissue or a cell type
within a tissue, and thus is less likely to have side effects
than the targets designed to the annotated forms of these
proteins, which are likely to be the most constitutive
isoforms. This calls for a systematic analysis directed at
obtaining a full transcript repertoire of such a ‘druggable’
transcriptome in a diverse set of cell types and tissues using
highly sensitive technologies, for example RACEarray
[2,3,21].
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EST, expressed sequence tag; RACE, rapid amplification of
cDNA ends.
C Co om mp pe et ti in ng g   i in nt te er re es st ts s
The author is an employee and stockholder of Helicos
BioSciences Corporation.
R Re ef fe er re en nc ce es s
1. ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA,
Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M,
Dermitzakis ET, Thurman RE, Kuehn MS, Taylor CM, Neph S, Koch
CM, Asthana S, Malhotra A, Adzhubei I, Greenbaum JA, Andrews
RM, Flicek P, Boyle PJ, Cao H, Carter NP, Clelland GK, Davis S, Day
N, Dhami P, Dillon SC, Dorschner MO, et al.:  I Id de en nt ti if fi ic ca at ti io on n    a an nd d
a an na al ly ys si is s   o of f   f fu un nc ct ti io on na al l   e el le em me en nt ts s   i in n   1 1% %   o of f   t th he e   h hu um ma an n   g ge en no om me e   b by y   t th he e
E EN NC CO OD DE E   p pi il lo ot t   p pr ro oj je ec ct t. .   Nature 2007, 4 44 47 7: :799-816.
2. Djebali S, Kapranov P, Foissac S, Lagarde J, Reymond A, Ucla C,
Wyss C, Drenkow J, Dumais E, Murray RR, Lin C, Szeto D, Denoeud
F, Calvo M, Frankish A, Harrow J, Makrythanasis P, Vidal M, Salehi-
Ashtiani K, Antonarakis SE, Gingeras TR, Guigó R: E Ef ff fi ic ci ie en nt t   t ta ar rg ge et te ed d
t tr ra an ns sc cr ri ip pt t   d di is sc co ov ve er ry y   v vi ia a   a ar rr ra ay y- -b ba as se ed d   n no or rm ma al li iz za at ti io on n   o of f   R RA AC CE E   l li ib br ra ar ri ie es s. .
Nat Methods 2008, 5 5: :629-635.
3. Denoeud F, Kapranov P, Ucla C, Frankish A, Castelo R, Drenkow J,
Lagarde J, Alioto T, Manzano C, Chrast J, Dike S, Wyss C, Henrich-
sen CN, Holroyd N, Dickson MC, Taylor R, Hance Z, Foissac S,
Myers RM, Rogers J, Hubbard T, Harrow J, Guigó R, Gingeras TR,
Antonarakis SE, Reymond A: P Pr ro om mi in ne en nt t   u us se e   o of f   d di is st ta al l   5 5’ ’   t tr ra an ns sc cr ri ip pt ti io on n
s st ta ar rt t   s si it te es s   a an nd d   d di is sc co ov ve er ry y   o of f   a a   l la ar rg ge e   n nu um mb be er r   o of f   a ad dd di it ti io on na al l   e ex xo on ns s   i in n
E EN NC CO OD DE E   r re eg gi io on ns s. .   Genome Res 2007, 1 17 7: :746-759.
4. Gingeras TR: O Or ri ig gi in n   o of f   p ph he en no ot ty yp pe es s: :   g ge en ne es s   a an nd d   t tr ra an ns sc cr ri ip pt ts s. .   Genome
Res 2007, 1 17 7: :682-690.
5. Kapranov P, Willingham AT, Gingeras TR: G Ge en no om me e- -w wi id de e   t tr ra an ns sc cr ri ip p- -
t ti io on n   a an nd d   t th he e   i im mp pl li ic ca at ti io on ns s   f fo or r   g ge en no om mi ic c   o or rg ga an ni iz za at ti io on n. .   Nat Rev Genet
2007, 8 8: :413-423.
6. Parra G, Reymond A, Dabbouseh N, Dermitzakis ET, Castelo R,
Thomson TM, Antonarakis SE, Guigo R: T Ta an nd de em m    c ch hi im me er ri is sm m    a as s    a a
m me ea an ns s    t to o    i in nc cr re ea as se e    p pr ro ot te ei in n    c co om mp pl le ex xi it ty y    i in n    t th he e    h hu um ma an n    g ge en no om me e. .
Genome Res 2006, 1 16 6: :37-44.
7. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N,
Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K,
Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ,
Wilming LG, Aidinis V, Allen JE, Ambesi-Impiombato A, Apweiler R,
Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T,
Bono H, et al.:  T Th he e    t tr ra an ns sc cr ri ip pt ti io on na al l    l la an nd ds sc ca ap pe e    o of f    t th he e    m ma am mm ma al li ia an n
g ge en no om me e. .   Science 2005, 3 30 09 9: :1559-1563.
8. Harrow J, Denoeud F, Frankish A, Reymond A, Chen CK, Chrast J,
Lagarde J, Gilbert JG, Storey R, Swarbreck D, Rossier C, Ucla C,
Hubbard T, Antonarakis SE, Guigo R: G GE EN NC CO OD DE E: :   p pr ro od du uc ci in ng g   a a   r re ef fe er r- -
e en nc ce e   a an nn no ot ta at ti io on n   f fo or r   E EN NC CO OD DE E. .   Genome Biol 2006, 7 7( (S Su up pp pl l   1 1) ): :S4.
9. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C,
Kingsmore SF, Schroth GP, Burge CB: A Al lt te er rn na at ti iv ve e   i is so of fo or rm m   r re eg gu ul la at ti io on n
i in n   h hu um ma an n   t ti is ss su ue e   t tr ra an ns sc cr ri ip pt to om me es s. .   Nature 2008, 4 45 56 6: :470-476.
10. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N,
Redon R, Bird CP, de Grassi A, Lee C, Tyler-Smith C, Carter N,
Scherer SW, Tavaré S, Deloukas P, Hurles ME, Dermitzakis ET: R Re el la a- -
t ti iv ve e   i im mp pa ac ct t   o of f   n nu uc cl le eo ot ti id de e   a an nd d   c co op py y   n nu um mb be er r   v va ar ri ia at ti io on n   o on n   g ge en ne e   e ex xp pr re es s- -
s si io on n   p ph he en no ot ty yp pe es s. .   Science 2007, 3 31 15 5: :848-853.
11. Merla G, Howald C, Henrichsen CN, Lyle R, Wyss C, Zabot MT,
Antonarakis SE, Reymond A: S Su ub bm mi ic cr ro os sc co op pi ic c    d de el le et ti io on n    i in n    p pa at ti ie en nt ts s
w wi it th h   W Wi il ll li ia am ms s- -B Be eu ur re en n   s sy yn nd dr ro om me e   i in nf fl lu ue en nc ce es s   e ex xp pr re es ss si io on n   l le ev ve el ls s   o of f   t th he e
n no on nh he em mi iz zy yg go ou us s   f fl la an nk ki in ng g   g ge en ne es s. .   Am J Hum Genet 2006, 7 79 9: :332-341.
http://genomemedicine.com/content/1/5/50 Genome Medicine 2009, Volume 1, Issue 5, Article 50 Kapranov 50.3
Genome Medicine 2009, 1 1: :5012. Storz G, Altuvia S, Wassarman KM: A An n   a ab bu un nd da an nc ce e   o of f   R RN NA A   r re eg gu ul la a- -
t to or rs s. .   Annu Rev Biochem 2005, 7 74 4: :199-217.
13. Baskerville S, Bartel DP: M Mi ic cr ro oa ar rr ra ay y   p pr ro of fi il li in ng g   o of f   m mi ic cr ro oR RN NA As s   r re ev ve ea al ls s
f fr re eq qu ue en nt t    c co oe ex xp pr re es ss si io on n    w wi it th h    n ne ei ig gh hb bo or ri in ng g    m mi iR RN NA As s    a an nd d    h ho os st t    g ge en ne es s. .
RNA 2005, 1 11 1: :241-247.
14. Kiss T: S Sm ma al ll l    n nu uc cl le eo ol la ar r    R RN NA As s: :    a an n    a ab bu un nd da an nt t    g gr ro ou up p    o of f    n no on nc co od di in ng g
R RN NA As s   w wi it th h   d di iv ve er rs se e   c ce el ll lu ul la ar r   f fu un nc ct ti io on ns s. .   Cell 2002, 1 10 09 9: :145-148.
15. Borel C, Antonarakis SE: F Fu un nc ct ti io on na al l    g ge en ne et ti ic c    v va ar ri ia at ti io on n    o of f    h hu um ma an n
m mi iR RN NA As s   a an nd d   p ph he en no ot ty yp pi ic c   c co on ns se eq qu ue en nc ce es s. .   Mamm Genome 2008, 1 19 9: :
503-509.
16. Affymetrix ENCODE Transcriptome Project; Cold Spring Harbor
Laboratory ENCODE Transcriptome Project: P Po os st t- -t tr ra an ns sc cr ri ip pt ti io on na al l
p pr ro oc ce es ss si in ng g   g ge en ne er ra at te es s   a a   d di iv ve er rs si it ty y   o of f   5 5’ ’- -m mo od di if fi ie ed d   l lo on ng g   a an nd d   s sh ho or rt t   R RN NA As s. .
Nature 2009, 4 45 57 7: :1028-1032.
17. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT,
Stadler PF, Hertel J, Hackermüller J, Hofacker IL, Bell I, Cheung E,
Drenkow J, Dumais E, Patel S, Helt G, Ganesh M, Ghosh S, Piccol-
boni A, Sementchenko V, Tammana H, Gingeras TR: R RN NA A    m ma ap ps s
r re ev ve ea al l   n ne ew w   R RN NA A   c cl la as ss se es s   a an nd d   a a   p po os ss si ib bl le e   f fu un nc ct ti io on n   f fo or r   p pe er rv va as si iv ve e   t tr ra an n- -
s sc cr ri ip pt ti io on n. .   Science 2007, 3 31 16 6: :1484-1488.
18. Kampa D, Cheng J, Kapranov P, Yamanaka M, Brubaker S, Cawley S,
Drenkow J, Piccolboni A, Bekiranov S, Helt G, Tammana H, Gingeras
TR: N No ov ve el l   R RN NA As s   i id de en nt ti if fi ie ed d   f fr ro om m   a an n   i in n- -d de ep pt th h   a an na al ly ys si is s   o of f   t th he e   t tr ra an ns sc cr ri ip p- -
t to om me e   o of f   h hu um ma an n   c ch hr ro om mo os so om me es s   2 21 1   a an nd d   2 22 2. . Genome Res 2004, 1 14 4: :331-
342.
19. Reis EM, Nakaya HI, Louro R, Canavez FC, Flatschart AV, Almeida
GT, Egidio CM, Paquola AC, Machado AA, Festa F, Yamamoto D,
Alvarenga R, da Silva CC, Brito GC, Simon SD, Moreira-Filho CA,
Leite KR, Camara-Lopes LH, Campos FS, Gimba E, Vignal GM, El-
Dorry H, Sogayar MC, Barcinski MA, da Silva AM, Verjovski-Almeida
S: A An nt ti is se en ns se e   i in nt tr ro on ni ic c   n no on n- -c co od di in ng g   R RN NA A   l le ev ve el ls s   c co or rr re el la at te e   t to o   t th he e   d de eg gr re ee e
o of f    t tu um mo or r    d di if ff fe er re en nt ti ia at ti io on n    i in n    p pr ro os st ta at te e    c ca an nc ce er r. .    Oncogene  2004,
2 23 3: :6684-6692.
20. Reis EM, Ojopi EP, Alberto FL, Rahal P, Tsukumo F, Mancini UM,
Guimarães GS, Thompson GM, Camacho C, Miracca E, Carvalho AL,
Machado AA, Paquola AC, Cerutti JM, da Silva AM, Pereira GG,
Valentini SR, Nagai MA, Kowalski LP, Verjovski-Almeida S, Tajara EH,
Dias-Neto E, Bengtson MH, Canevari RA, Carazzolle MF, Colin C,
Costa FF, Costa MC, Estécio MR, Esteves LI, et al.: L La ar rg ge e- -s sc ca al le e   t tr ra an n- -
s sc cr ri ip pt to om me e   a an na al ly ys se es s   r re ev ve ea al l   n ne ew w   g ge en ne et ti ic c   m ma ar rk ke er r   c ca an nd di id da at te es s   o of f   h he ea ad d, ,
n ne ec ck k, ,   a an nd d   t th hy yr ro oi id d   c ca an nc ce er r. .   Cancer Res 2005, 6 65 5: :1693-1699.
21. Kapranov P, Drenkow J, Cheng J, Long J, Helt G, Dike S, Gingeras
TR: E Ex xa am mp pl le es s   o of f   t th he e   c co om mp pl le ex x   a ar rc ch hi it te ec ct tu ur re e   o of f   t th he e   h hu um ma an n   t tr ra an ns sc cr ri ip p- -
t to om me e   r re ev ve ea al le ed d   b by y   R RA AC CE E   a an nd d   h hi ig gh h- -d de en ns si it ty y   t ti il li in ng g   a ar rr ra ay ys s. .   Genome Res
2005, 1 15 5: :987-997.
http://genomemedicine.com/content/1/5/50 Genome Medicine 2009, Volume 1, Issue 5, Article 50 Kapranov 50.4
Genome Medicine 2009, 1 1: :50